2 transplant drugs based on stem cells are in development

07/10/2009 | Bloomberg

Novartis and Fate Therapeutics are competing to develop a cancer drug based on stem cells for transplant patients struggling to find matching bone marrow or umbilical cord blood. Fate Therapeutics started a clinical trial of its candidate, FT1050, in collaboration with the Harvard Stem Cell Institute. The University of Minnesota might conduct human trials of Novartis' experimental treatment next year.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA